Supplement to Framework for Advances in Reprogenomics Ethics & Regulation (FAIRER)
生殖基因组学伦理进展框架的补充
基本信息
- 批准号:10593247
- 负责人:
- 金额:$ 15.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdministrative SupplementAdvocateAreaAssisted Reproductive TechnologyBioethicsBioethics ConsultantsBiomedical ResearchChildClinicalClinical ResearchClinical TrialsConduct Clinical TrialsData CollectionDevelopmentEnsureEthical IssuesEthicsFamilyFeedbackFocus GroupsFundingFutureGeneticGenomicsHealthHealth Care ResearchHealthcareHeterosexualsHumanHuman GenomeIndividualInstitutional Review BoardsInterventionInterviewLiteratureMedicalModificationMotivationOutputParentsParticipantPatientsPersonal SatisfactionPersonsPhysiologicalPolicy MakerPopulation HeterogeneityPregnancyPrivacyQualitative MethodsRegulationReproductionReproductive MedicineReproductive SciencesResearchResearch EthicsResearch MethodologyResearch PersonnelReview LiteratureSafetyScienceScientistSexual DevelopmentSocial SciencesSocietiesStructureTrustUnderrepresented PopulationsWorkcisgendercommunity based researchdesignepigenomeexperiencegender minoritygender minority communitygender minority groupgender minority healthinsightinterestmeetingsmembermicrobiomeminority healthcareoffspringparent projectpregnantreproductivesexual minoritysexual minority groupsocialsocial exclusionsocial movementtransgendertrial design
项目摘要
ABSTRACT
The FAIRER study is designed to develop a framework for the ethical conduct of clinical trials of reproductive
genomic interventions, particularly focusing on the research participation of pregnancy-capable individuals.
This supplement to the FAIRER study will address unique ethical and social issues in trials involving research
participants from sexual and/or gender minorities (SGM). The motivations and considerations of SGM
regarding reproductive genomic interventions, while sharing common features with those of cisgender and
heterosexual participants, likely also differ in significant ways. Physiological, genetic, and social differences
between cisgender participants, transgender participants, and those with differences of sexual development
(DSD) may necessitate changes in trial design and safety considerations. Finally, SGM have historically
experienced marginalization in medical settings, particularly with respect to access to and utilization of assisted
reproductive technologies, that impact trust relationships in biomedical research. In order to build an ethical
framework that considers the needs and interests of all potential participants in reprogenomics clinical trials,
this project has the following Aims: (1) Incorporate considerations unique to individuals identifying as sexual
and/or gender minorities (SGM) into an ethical framework for reprogenomics research, with emphasis on the
health and well-being of pregnant and potentially pregnant participants and their future offspring; and (2) Build
the perspectives and expertise of SGM individuals and experts in SGM healthcare and research into our
ethical framework and the stakeholder-informed toolkit to guide IRBs and researchers engaged with
reprogenomics. To accomplish these Aims, we will conduct a scoping review of literature on SGM
considerations in family-building; interview professionals with expertise in SGM health to draft an ethical
framework that addresses issues relevant to SGM clinical participation; and conduct two focus groups with
individuals from SGM communities to discuss and receive feedback on the draft framework. These strategies
will enhance our larger project and increase the relevance of its results and deliverables to all stakeholders
who may be involved in future human research in reprogenomics.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ruth Farrell其他文献
Ruth Farrell的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ruth Farrell', 18)}}的其他基金
Framework for Advances in Reprogenomics Ethics & Regulation (FAIRER)
生殖基因组学伦理进展框架
- 批准号:
10408663 - 财政年份:2021
- 资助金额:
$ 15.12万 - 项目类别:
Framework for Advances in Reprogenomics Ethics & Regulation (FAIRER)
生殖基因组学伦理进展框架
- 批准号:
10596652 - 财政年份:2021
- 资助金额:
$ 15.12万 - 项目类别:
Admin. Supplement to: Ensuring Patients' Informed Access to Noninvasive Prenatal Testing
行政。
- 批准号:
10165356 - 财政年份:2017
- 资助金额:
$ 15.12万 - 项目类别:
Ensuring Patients' Informed Access to Noninvasive Prenatal Testing
确保患者知情地获得无创产前检测
- 批准号:
9751355 - 财政年份:2017
- 资助金额:
$ 15.12万 - 项目类别:
Engaging Patients in Prenatal Genetic Testing Decisions as a Pathway to Improve Obstetric Outcomes
让患者参与产前基因检测决策作为改善产科结果的途径
- 批准号:
10658430 - 财政年份:2017
- 资助金额:
$ 15.12万 - 项目类别:
Preparing for Emerging Applications of Noninvasive Prenatal Testing
为无创产前检测的新兴应用做好准备
- 批准号:
8871291 - 财政年份:2015
- 资助金额:
$ 15.12万 - 项目类别:
Patient perceptions of bioengineered probiotics and clinical metagenomics
患者对生物工程益生菌和临床宏基因组学的看法
- 批准号:
7908705 - 财政年份:2008
- 资助金额:
$ 15.12万 - 项目类别:
Patient perceptions of bioengineered probiotics and clinical metagenomics
患者对生物工程益生菌和临床宏基因组学的看法
- 批准号:
7572423 - 财政年份:2008
- 资助金额:
$ 15.12万 - 项目类别:
Patient perceptions of bioengineered probiotics and clinical metagenomics
患者对生物工程益生菌和临床宏基因组学的看法
- 批准号:
7690965 - 财政年份:2008
- 资助金额:
$ 15.12万 - 项目类别:
相似海外基金
A Longitudinal Qualitative Study of Fentanyl-Stimulant Polysubstance Use Among People Experiencing Homelessness (Administrative supplement)
无家可归者使用芬太尼兴奋剂多物质的纵向定性研究(行政补充)
- 批准号:
10841820 - 财政年份:2023
- 资助金额:
$ 15.12万 - 项目类别:
Proton-secreting epithelial cells as key modulators of epididymal mucosal immunity - Administrative Supplement
质子分泌上皮细胞作为附睾粘膜免疫的关键调节剂 - 行政补充
- 批准号:
10833895 - 财政年份:2023
- 资助金额:
$ 15.12万 - 项目类别:
Administrative Supplement: Life-Space and Activity Digital Markers for Detection of Cognitive Decline in Community-Dwelling Older Adults: The RAMS Study
行政补充:用于检测社区老年人认知衰退的生活空间和活动数字标记:RAMS 研究
- 批准号:
10844667 - 财政年份:2023
- 资助金额:
$ 15.12万 - 项目类别:
StrokeNet Administrative Supplement for the Funding Extension
StrokeNet 资助延期行政补充文件
- 批准号:
10850135 - 财政年份:2023
- 资助金额:
$ 15.12万 - 项目类别:
2023 NINDS Landis Mentorship Award - Administrative Supplement to NS121106 Control of Axon Initial Segment in Epilepsy
2023 年 NINDS 兰迪斯指导奖 - NS121106 癫痫轴突初始段控制的行政补充
- 批准号:
10896844 - 财政年份:2023
- 资助金额:
$ 15.12万 - 项目类别:
Biomarkers of Disease in Alcoholic Hepatitis Administrative Supplement
酒精性肝炎行政补充剂中疾病的生物标志物
- 批准号:
10840220 - 财政年份:2023
- 资助金额:
$ 15.12万 - 项目类别:
Administrative Supplement: Improving Inference of Genetic Architecture and Selection with African Genomes
行政补充:利用非洲基因组改进遗传结构的推断和选择
- 批准号:
10891050 - 财政年份:2023
- 资助金额:
$ 15.12万 - 项目类别:
Power-Up Study Administrative Supplement to Promote Diversity
促进多元化的 Power-Up 研究行政补充
- 批准号:
10711717 - 财政年份:2023
- 资助金额:
$ 15.12万 - 项目类别:
Administrative Supplement for Peer-Delivered and Technology-Assisted Integrated Illness Management and Recovery
同行交付和技术辅助的综合疾病管理和康复的行政补充
- 批准号:
10811292 - 财政年份:2023
- 资助金额:
$ 15.12万 - 项目类别:
Sedentary behavior, physical activity, and 24-hour behavior in pregnancy and offspring health: the Pregnancy 24/7 Offspring Study Administrative Supplement
久坐行为、体力活动和 24 小时行为对怀孕和后代健康的影响:怀孕 24/7 后代研究行政补充
- 批准号:
10893074 - 财政年份:2023
- 资助金额:
$ 15.12万 - 项目类别: